ZLAB Zai Lab Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1704292 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.0%
TTM net income YoY4.1%
TTM EPS YoY5.3%
Revenue 3-yr CAGR18.8%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin-63.0%
Net margin-44.9%
FCF margin-37.0%
EBITDA margin-60.1%
Returns
ROE-30.0%
ROA-18.2%
ROIC (approx.)-779.4%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-45.16x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $460.16M | $398.99M | $266.72M | $215.04M | $144.31M |
| Cost of revenue | $190.52M | $147.12M | $95.82M | $74.02M | $52.24M |
| Gross profit | $269.64M | $251.87M | $170.90M | $141.02M | $92.07M |
| R&D expense | $220.90M | $234.50M | $265.87M | $286.41M | $573.31M |
| SG&A expense | $277.61M | $298.74M | $281.61M | $258.97M | $218.83M |
| Operating income | -$229.43M | -$282.12M | -$366.57M | -$404.36M | -$700.06M |
| Interest expense | $5.21M | $2.25M | $0 | $0 | $0 |
| Pretax income | -$178.46M | -$257.10M | -$334.62M | -$443.29M | -$704.47M |
| Income tax | -$2.93M | $0 | $0 | $0 | $0 |
| Net income | -$175.54M | -$257.10M | -$334.62M | -$443.29M | -$704.47M |
| EBITDA | -$214.42M | -$270.26M | -$357.54M | -$396.13M | -$693.58M |
| EPS (basic) | -0.16 | -0.26 | -0.35 | -0.46 | -0.76 |
| EPS (diluted) | -0.16 | -0.26 | -0.35 | -0.46 | -0.76 |
| Weighted avg. shares (diluted) | 1.10B | 989.48M | 966.39M | 958.07M | 929.92M |
| Balance sheet | |||||
| Cash & equivalents | $679.57M | $449.67M | $790.15M | $1.01B | $964.10M |
| Short-term investments | $10.00M | $330.00M | $16.30M | $0 | $445.00M |
| Receivables | $106.12M | $85.18M | $59.20M | $39.96M | $47.47M |
| Inventory | $74.75M | $39.88M | $44.83M | $31.62M | $18.95M |
| Current assets | $1.02B | $1.05B | $939.61M | $1.12B | $1.50B |
| PP&E, net | $47.39M | $47.96M | $53.73M | $57.86M | $43.10M |
| Intangibles | $76.14M | $56.03M | $13.39M | $1.51M | $1.85M |
| Total assets | $1.17B | $1.19B | $1.04B | $1.22B | $1.61B |
| Current liabilities | $416.17M | $299.38M | $203.07M | $139.84M | $192.90M |
| Short-term debt | $204.53M | $131.71M | $0 | — | — |
| Total liabilities | $456.88M | $344.86M | $240.18M | $174.54M | $230.00M |
| Shareholders' equity | $715.50M | $840.90M | $796.12M | $1.05B | $1.38B |
| Shares outstanding | 1.11B | 1.08B | 972.24M | 960.22M | 954.98M |
| Cash flow statement | |||||
| Operating cash flow | -$150.79M | -$214.87M | -$198.18M | -$367.64M | -$549.23M |
| Capital expenditure | $8.10M | $5.66M | $7.21M | $24.59M | $18.30M |
| Free cash flow | -$158.89M | -$220.53M | -$205.39M | -$392.23M | -$567.53M |
| Investing cash flow | $307.87M | -$375.19M | -$10.78M | $420.02M | $249.96M |
| Financing cash flow | $72.35M | $349.89M | -$6.43M | -$1.73M | $820.20M |
| Depreciation & amortization | $15.01M | $11.86M | $9.03M | $8.23M | $6.49M |
| Stock-based compensation | $65.60M | $70.65M | $79.63M | $61.30M | $40.71M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.